Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03541200 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms
A Phase 2 study, sponsored by Tanabe Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
NCT03541200 is a Phase 2 study that has completed, run by Tanabe Pharma America. The registered enrollment target is 190 participants.
The verdict
NCT03541200, a Phase 2 study, has completed, sponsored by Tanabe Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
Study Summary
An open-label, long term extension study of MT-8554 in postmenopausal women experiencing moderate to severe vasomotor symptoms who completed Study MT-8554-A01
Interventions
- DRUG MT-8554
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2019-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03541200
The ClinicalTrials.gov registry entry for NCT03541200 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tanabe Pharma America, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MT-8554 is the first listed.
NCT03541200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03541200 about?
NCT03541200 is a clinical study titled "Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms". An open-label, long term extension study of MT-8554 in postmenopausal women experiencing moderate to severe vasomotor symptoms who completed Study MT-8554-A01
What is the current status of trial NCT03541200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2018-04-18. Estimated completion is 2019-11-15.
What interventions are being tested in trial NCT03541200?
The interventions under investigation include: MT-8554 (DRUG).
Who is sponsoring clinical trial NCT03541200?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.